NP
VRTX icon

NorthRock Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

NorthRock Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$482K Sell
1,079
-6
-0.6% -$2.8K 0.01% 422
2025
Q4 		$492K Sell
1,085
-2,367
-69% -$1.02M 0.01% 367
2025
Q3 		$1.35M Buy
3,452
+276
+9% +$115K 0.02% 280
2025
Q2 		$1.41M Sell
3,176
-98
-3% -$45.2K 0.04% 179
2025
Q1 		$1.59M Buy
3,274
+349
+12% +$163K 0.05% 143
2024
Q4 		$1.18M Sell
2,925
-377
-11% -$175K 0.04% 183
2024
Q3 		$1.54M Buy
3,302
+67
+2% +$32.2K 0.05% 152
2024
Q2 		$1.52M Buy
3,235
+132
+4% +$57.3K 0.06% 144
2024
Q1 		$1.3M Buy
3,103
+281
+10% +$119K 0.05% 163
2023
Q4 		$1.15M Buy
2,822
+1,333
+90% +$492K 0.05% 170
2023
Q3 		$518K Buy
1,489
+514
+53% +$180K 0.05% 153
2023
Q2 		$343K Buy
975
+101
+12% +$34K 0.04% 193
2023
Q1 		$275K Sell
874
-255
-23% -$76.5K 0.03% 242
2022
Q4 		$326K Buy
1,129
+155
+16% +$47.2K 0.04% 233
2022
Q3 		$282K Buy
974
+47
+5% +$13.5K 0.03% 214
2022
Q2 		$261K Buy
+927
New +$248K 0.03% 248

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NorthRock Partners's VRTX Position: Q1 2026 in Review

NorthRock Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 0.55% in Q1 2026, selling an estimated $2.8K and leaving 1,079 shares worth $482K. The position accounts for 0.01% of the portfolio, ranked #422.

NorthRock Partners first reported a position in VRTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.59M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • NorthRock Partners held 1,079 shares of Vertex Pharmaceuticals worth $482K as of Q1 2026.
  • NorthRock Partners sold 6 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.8K.
  • Vertex Pharmaceuticals made up 0.01% of NorthRock Partners's portfolio in Q1 2026, its #422 holding.
  • NorthRock Partners first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • NorthRock Partners's Vertex Pharmaceuticals position peaked at $1.59M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on NorthRock Partners's 13F filing for Q1 2026, filed 15 May 2026.